Double-Dose Pravastatin Versus Add-On Ezetimibe with Low-Dose Pravastatin -Effects on LDL Cholesterol, Cholesterol Absorption, and Cholesterol Synthesis in Japanese Patients with Hypercholesterolemia (PEAS study)

Jun Sasaki, Takatoshi Otonari, Yasunori Sawayama, Shiro Hata, Yoshimi Oshima, Tetsunori Saikawa, Sadatoshi Biro, Suminori Kono
2012 Journal of atherosclerosis and thrombosis  
Aim: This study compared the effect of doubling the dose of pravastatin with that of adding ezetimibe to low-dose pravastatin on the LDL cholesterol (LDL-C) level and on cholesterol absorption and synthesis markers. The tolerability of the 2 regimens was also compared. Methods: This was a multicenter, open-label, parallel-group trial. Subjects were aged from 20 to 74 years and had an LDL-C ≥120 mg/dL despite pravastatin therapy at 5-10 mg/day. They were randomly allocated to receive either
more » ... receive either add-on ezetimibe (10 mg/day) or double-dose pravastatin, and follow-up was performed for 12 weeks. The primary endpoints were the changes of LDL-C and apolipoprotein (apo) B levels after 12 weeks of treatment. Cholesterol absorption and synthesis markers were also determined. Results: LDL-C and apo B decreased by 16% and 14% in the ezetimibe add-on group versus 5.9% and 4.4%, respectively, in the pravastatin double-dose group. The between-group differences of these decreases were highly significant. Cholesterol absorption markers (sitosterol, campesterol, and cholestanol) were reduced by 48%, 36%, and 10%, respectively, in the ezetimibe add-on group, and were increased by 17%, 14%, and 6%, respectively, in the pravastatin double-dose group. Lathosterol (a cholesterol synthesis marker) increased by 76% in the ezetimibe add-on group and by 24% in the pravastatin double-dose group. The difference was statistically significant. No serious adverse effect was observed in either group. Conclusions: Adding ezetimibe to low-dose pravastatin achieves greater decreases in LDL -C, apo B, and cholesterol absorption markers than doubling the dose of pravastatin. J Atheroscler Thromb, 2012; 19:485-493. Female, n (%) Age (year), mean (SD) Smoking, n (%) Regular alcohol use, n (%) Body weight (kg), mean (SD) BMI (kg/m 2 ), mean (SD) Waist (cm), mean (SD) Comorbidity Liver diseases, n (%) Hypertension, n (%) Antihypertensive drug, n (%) Diabetes/IGT, n (%) Antidiabetic drug, n (%) CAD, n (%) Prior history Myocardial infarction, n (%) Cerebral infarction, n (%) Parental CAD, n (%) Pravastatin 10 mg, n (%)
doi:10.5551/jat.12013 pmid:22659533 fatcat:3msy7plzgfebhj3sjwn5wgepoq